B-intervention	0	10	Exemestane
O	11	14	for
O	15	21	breast
O	22	28	cancer
O	29	39	prevention
O	39	40	:
O	41	42	a
O	43	51	critical
O	52	57	shift
O	57	58	?

O	59	62	The
O	63	70	Mammary
O	71	81	Prevention
O	82	83	3
O	84	85	(
O	85	88	MAP
O	88	89	.
O	89	90	3
O	90	91	)
O	92	99	placebo
O	99	100	-
O	100	110	controlled
O	111	121	randomized
O	122	127	trial
O	128	130	in
B-total-participants	131	132	4
I-total-participants	132	133	,
I-total-participants	133	136	560
B-eligibility	137	141	high
I-eligibility	141	142	-
I-eligibility	142	146	risk
I-eligibility	147	161	postmenopausal
I-eligibility	162	167	women
O	168	174	showed
O	175	176	a
B-iv-bin-percent	177	179	65
I-iv-bin-percent	179	180	%
B-outcome	181	190	reduction
I-outcome	191	193	in
I-outcome	194	202	invasive
I-outcome	203	209	breast
I-outcome	210	216	cancer
O	217	221	with
O	222	225	the
O	226	229	use
O	230	232	of
O	233	243	exemestane
O	244	246	at
O	247	249	35
O	250	256	months
O	257	263	median
O	264	270	follow
O	270	271	-
O	271	273	up
O	273	274	.

O	275	278	Few
O	279	290	differences
O	291	293	in
B-outcome	294	301	adverse
I-outcome	302	308	events
O	309	313	were
O	314	322	observed
O	323	330	between
O	331	334	the
O	335	339	arms
O	339	340	,
O	341	351	suggesting
O	352	353	a
O	354	363	promising
O	364	368	risk
O	368	369	:
O	369	376	benefit
O	377	384	balance
O	385	389	with
O	390	400	exemestane
O	401	404	for
O	405	408	use
O	409	411	in
O	412	427	chemoprevention
O	427	428	.

O	429	432	Yet
O	432	433	,
O	434	437	the
O	438	441	MAP
O	441	442	.
O	442	443	3
O	444	450	design
O	451	454	and
O	455	469	implementation
O	470	475	raise
O	476	484	concerns
O	485	494	regarding
O	495	502	limited
O	503	507	data
O	508	516	maturity
O	517	520	and
O	521	524	not
O	525	538	prospectively
O	539	548	including
O	549	552	key
O	553	557	bone
O	557	558	-
O	558	565	related
O	566	569	and
O	570	575	other
O	576	586	toxicities
O	587	589	as
O	590	595	study
O	596	599	end
O	600	606	points
O	606	607	.

O	608	618	Exemestane
O	619	622	for
O	623	633	prevention
O	634	636	is
O	637	647	juxtaposed
O	648	655	against
O	656	665	selective
O	666	674	estrogen
O	675	683	receptor
O	684	694	modulators
O	695	698	and
O	699	702	the
O	703	708	other
O	709	718	aromatase
O	719	729	inhibitors
O	729	730	.

O	731	741	Additional
O	742	748	issues
O	749	752	for
O	753	763	prevention
O	763	764	,
O	765	774	including
O	775	778	the
O	779	788	influence
O	789	791	of
O	792	799	obesity
O	799	800	,
O	801	812	alternative
O	813	819	dosing
O	819	820	,
O	821	824	and
O	825	834	biomarker
O	835	838	use
O	839	841	in
O	842	847	phase
O	848	851	III
O	852	858	trials
O	858	859	,
O	860	863	are
O	864	873	addressed
O	873	874	.

O	875	878	The
O	879	887	recently
O	888	897	completed
O	898	901	MAP
O	901	902	.
O	902	903	3
O	904	909	trial
O	910	912	of
O	913	923	exemestane
O	924	927	for
O	928	934	breast
O	935	941	cancer
O	942	952	prevention
O	953	959	offers
O	960	961	a
O	962	971	potential
O	972	975	new
O	976	984	standard
O	985	988	for
O	989	1003	pharmaceutical
O	1004	1008	risk
O	1009	1018	reduction
O	1019	1021	in
O	1022	1026	high
O	1026	1027	-
O	1027	1031	risk
O	1032	1046	postmenopausal
O	1047	1052	women
O	1052	1053	.

O	1054	1056	In
O	1057	1065	addition
O	1066	1068	to
O	1069	1079	describing
O	1080	1083	key
O	1084	1092	findings
O	1093	1097	from
O	1098	1101	the
O	1102	1113	publication
O	1114	1116	of
O	1117	1120	MAP
O	1120	1121	.
O	1121	1122	3
O	1123	1126	and
O	1127	1134	related
O	1135	1141	trials
O	1141	1142	,
O	1143	1146	our
O	1147	1153	review
O	1154	1164	undertakes
O	1165	1166	a
O	1167	1175	detailed
O	1176	1184	analysis
O	1185	1187	of
O	1188	1191	the
O	1192	1201	strengths
O	1202	1205	and
O	1206	1216	weaknesses
O	1217	1219	of
O	1220	1223	MAP
O	1223	1224	.
O	1224	1225	3
O	1226	1228	as
O	1229	1233	well
O	1234	1236	as
O	1237	1240	the
O	1241	1253	implications
O	1254	1257	for
O	1258	1264	future
O	1265	1275	prevention
O	1276	1284	research
O	1284	1285	.
